

REFERÊNCIAS BIBLIOGRÁFICAS



7. REFERÊNCIAS BIBLIOGRÁFICAS

1. Hansen GHA. Üdersogelsen angaend spedalskhendens arsager. Norsk Laegevil 1873; 4:1-88.
2. Noordeen SK. Eliminating leprosy as a public health problem: why the optimism is justified. Int J Lepr Other Mycobact Dis 1995; 63: 559-66.
3. World Health Organization. Progress towards the elimination of leprosy as a public health problem. Weekly Epidemiol rec 1993; 68: 181.
4. Brasil. Ministério da Saúde. Secretaria de Políticas de Saúde. Departamento de Atenção Básica. Guia para controle da Hanseníase. Brasília; 2002.
5. Talhari S, Neves RG. Hansenologia. Manaus: Calderaro Ltda; 1984.
6. Brennan PJ. Structure of mycobacteria: recent developments in defining cell wall carbohydrates and proteins. Rev Infect Dis 1989; 11: 420-30.
7. Hunter SW, Brennan PJ. A novel phenolic glycolipid from *Mycobacterium leprae* possibly involved in immunogenicity and pathogenicity. J Bacteriol 1981; 147: 728-35.
8. Hunter SW, Fujiwara T, Brennan PJ. Structure and antigenicity of the major specific glycolipid antigen of *Mycobacterium leprae*. J Biol Chem 1982; 257: 15072-8.

1 Comitê Internacional de Editores de Revistas Médicas. Requisitos uniformes para originais submetidos a revistas biomédicas. Ann Intern Méd 1997; 126:36-47.

National Library of Medicine. List of journals indexed In Index Medicus. Washington, 2003. 240p.

Referências Bibliográficas

9. Young DB. Detection of mycobacterial lipids in skin biopsies from leprosy patients. *Int J Lepr Other Mycobact Dis* 1981; 49: 198-204.
10. Jopling WH, McDougall AC, Bakos L. Manual da Hanseníase. 4.ed. Rio de Janeiro: Atheneu; 1991.
11. Rees RJW. The microbiology of leprosy. In: Hastings RC, editor. *Leprosy*. 4th ed. Edinburg: Churchil Livingstone; 1994. p.49-83.
12. Shepard CC. The nasal excretions of *Mycobacterium /eprae* in leprosy. *Int J Lepr* 1962; 30:10-8.
13. Davey TF, Rees RJW. The nasal discharge in leprosy: clinical and bacteriological aspects. *Lepr Rev* 1974; 45:121-34.
14. Opromolla DVA, Ura S. Epidemiologia. In: *Noções de Hansenologia*. 2.ed. Bauru: Centro de Estudos "Dr Reynaldo Quagliato". Instituto Lauro de Souza Lima, 2000. p.101-7.
15. Organização Mundial da Saúde. WHO Expert Committee on leprosy: fourth report. *Tech Rep Ser/ World Health Organ* 1977; 607:1-48.
16. Bechelli LM, Curban GV. Lepra. In: *Compêndio de Dermatologia*, 6.ed. São Paulo: Atheneu; 1988. p.132-63.
17. Pfaltzraff RE, Ramu G. Clinical leprosy. In: Hastings RC, Opromolla DVA. *Leprosy*. Edinburg: Churchill Livingstone, 2.ed. 1994. p.237-290.

Referências Bibliográficas

18. Talhari S, Neves RG. Manifestações cutâneas e diagnóstico diferencial. In: Hanseníase. 3.ed. Manaus: Dermatologia Tropical; 1997. p.5-40.
19. Opromolia DVA. Manifestações Clínicas e Reações. In: Noções de Hansenologia. 2ed. Bauru: Centro de Estudos "Dr Reynaldo Quagliato". Instituto Lauro de Souza Lima; 2000. p.51-58.
20. Memória Del 6th Congresso Internacional de Leprologia, 1953; Madrid: Association International de la Lepra, 1953. p. 1344.
21. Ridley DS, Jopling WH. Classification of Leprosy According to Immunity. A five- group system. Int J Lepr 1966; 34: 255-73.
22. World Health Organization. Chemotherapy of leprosy for control programmes. Tech Rep Ser/World Health Ogan. Gineve: 1982; 675: 37p.
23. Opromolla DVA. Terapêutica. In: Noções de Hansenologia. 2.ed. Bauru: Centro de Estudos "Dr Reynaldo Quagliato". Instituto Lauro de Souza Lima; 2000. p.95-99.
24. Organização Mundial da Saúde. Quimioterapia da Hanseníase para Programas de Estudos. Genebra; 1982. 37p. (série de informes técnicos, n.607).
25. Foss NT. Aspectos Imunológicos da hanseníase: immunological aspects of leprosy. Medicina (Ribeirão Preto) 1997; 30: 335-9.

26. Avila JL, Convit J. Studies on cellular immunity in leprosy. I Lysosomal enzymes. *Int J Lepr Other Mycobact Dis* 1970; 38: 359-64.
27. Modlin RL. Th1-Th2 paradigm: insights from leprosy. *J Invest Dermatol* 1994; 102: 828-32.
28. Goulart IMB, Penha GO, Cunha G. Imunopatologia da hanseníase: a complexidade dos mecanismos da resposta imune do hospedeiro ao *Mycobacterium leprae*. *Rev Soc Bras Med Trop* 2002; 35: 365-75.
29. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. *Science* 1991; 254: 277-79.
30. Sieling PA, Modlin RL. T cell and cytokine patterns in leprosy skin lesion. *Springer Semin Immunopathol* 1992; 13: 413-26.
31. Sieling PA, Modlin RL. Cytokine patterns at the site of mycobacterial infection. *Immunobiology* 1994; 191: 378-87.
32. Mutis T, Kraakman EM, Cornelisse YE, Haanen JB, Spits H, De Vries RR, et al. Analysis of cytokine production by *Mycobacterium*-reactive T cell. Failure to explain *Mycobacterium leprae* specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. *J Immunol* 1993; 150: 4641-51.
33. Barnetson R, Bjune G, Pearson JMH, Kronwall G. Cell mediated and humoral immunity in "reversal reactions". *Int J Lepr* 1976; 44: 267-73.

34. Naafs B. Leprosy reactions: new knowledge. Trop Geogr Med 1994; 46: 80-4.
35. Rea TH, Levan NE. Erythema nodosum leprosum in a general hospital. Arch Dermatol 1975; 111: 1575-80.
36. Smith C, Nocholl P, Braked WW, Lockwood D, Naafs B, Scollard D, et al. Special workshop on repeated and late reactions. Int J Lepr Other Mycobact Dis 2002; 70: 339-41.
37. Sampaio EP, Sarno EN. Expression and cytokine secretion in the states of immune reactivation in leprosy. Braz J Med Biol Res 1998; 31: 69-76.
38. Brennan PJ, Barrow WW. Evidence for species-specific lipid antigens in *Mycobacterium leprae*. Int J Lepr 1980; 48: 382-7.
39. Hunter SW, Brennan PJ. Further specific extracellular phenolic glycolipid antigens and a related diacylphthiocerol from *Mycobacterium leprae*. J Doi Chem 1983; 258: 7556-62.
40. Young DB, Buchanan TM. A serological test for leprosy with a glycolipid specific for *Mycobacterium leprae*. Science 1983; 221: 1057-9.
41. Fujiwara T, Hunter Sw, Cho SN, Aspinall GO, Brennan PJ. Chemical synthesis and serological of disaccharides and trisaccharides of phenolic glicolipid antigens from the leprosy bacillus and preparation of a disaccharide protein conjugate for serodiagnosis of leprosy. Infect Immun 1984; 43: 245-52.

42. Cho SN, Yanagihara DL, Hunter SW, Gelber RH, Brennan PJ. Serological specificity of phenolic glycolipid-I from *Mycobacterium leprae* and use in serodiagnosis of leprosy. *Infect Immun* 1983; 41: 1077-83.
43. Cruaud P, Yamashita JT, Casabona NM, Papa F, David HL. Evaluation of a novel 2,3-diacil-trehalose-2'-sulphate (SL-IV) antigen for case finding and diagnosis of leprosy and tuberculosis. *Res Microbiol* 1990; 141: 679-94.
44. Schwerer B, Meeker HC, Sersen G, Levis WR. IgM antibodies against phenolic glycolipid-I from *Mycobacterium leprae* in leprosy sera relationship to bacterial index and erythema nodosum leprosum. *Acta Leprol* 1984; 2: 395-402.
45. Maeda SM, Rotta O, Mychalany NS, Camargo ZP, Sunderkötter CE, Yamashita JT. Comparison between anti-PGL-I serology and Mitsuda reaction: clinical reading, microscopic findings and immunohistochemical analysis. *Lepr Rev* 2003; 74: 263-74.
46. Roche PW, Britton NJ, Neupane KD, Failbus SS, Cho SN, Theuvenet WJ. The response to chemotherapy of serum *Mycobacterium leprae*-specific antigen in multibacillary leprosy patients. *Am J Trop Med Hyg* 1991; 44: 702-8.
47. Neill MA, Klebanoff SJ. The effect of phenolic glycolipid-I from *Mycobacterium leprae* on the antimicrobial activity of human macrophages. *J Exp Med* 1988; 167: 30-42.

48. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, et al. Immune response associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. *J Exp Med* 1984; 160: 310-6.
49. Nathan CF. Peroxide and pteridine: a hypothesis of the regulation of macrophage antimicrobial activity by interferon-gamma. In: J Gresser. Ed Interferon. London: Academic Press 1986; p.125-43.
50. Woloszczuk W, Troppmair J, Leiter E, Flener R, Schwarz M, Kovarik J, et al. Relationship of interferon-gamma and neopterin levels during stimulation with alloantigens *in vivo* and *in vitro*. *Transplantation* 1986; 41: 716-9.
51. Huber C, Fuchs D, Hausen A, Margreiter R, Reibnegger G, Spielberger M, et al. Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC). *J Immunol* 1983; 130: 1047-50.
52. Hamerlinck FFV, Klaster PR, Walsh DS, Bos JD, Walsh GP, Faber WR. Serum neopterin as a marker for reactional states in leprosy. *FEMS Immunol Med Microbiol* 1999; 24: 405-9.
53. Fuchs D, Hausen A, Kofler M, Kosanowski H, Reibnegger G, Wachter H. Neopterin as an index of immune response in patients with tuberculosis. *Lung* 1984; 162: 337-46.
54. Reibnegger G, Boonpucknavig V, Fuchs D, Hausen A, Schmutzhard E, Wachter H. Urinary neopterin excretion is elevated in patients with malaria. *Trans R Soc Trop Med Hyg* 1984; 78: 545-6.

55. Hamerlink FF, van Goal T, Faber WR, Kager PA. Serum neopterin concentrations during treatment of leishmaniasis: useful as test of cure? *FEMS Immunol Med Microbiol* 2000; 27: 31-4.
56. Walmsley RN, White GH. *A guide to diagnostic clinical chemistry*. London: Blackwell, 1994.
57. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. *Adv Immunol* 1983; 34: 141-212.
58. Moshage HJ, Roelofs HMJ, Van Pelt JF, Hazenberg BPC, Van Leeuwen MA, Limburg PC, et al. The effect of interleukin-1 interleukin6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. *Biochem Biophys Res Commun* 1988; 155: 112-7.
59. Kushner I, Ganapathy M, Schultz D. The acute phase response is mediated by heterogeneous mechanisms. *Ann N Y Acad Sci* 1989; 557: 19-30.
60. Dinarello CA. Role of interleukin-1 in infectious diseases. *Immunol Rev* 1992; 127: 119-46.
61. Taylor AW, Ku No, Mortensen RF. Both human IL-1 and IL-6 induce synthesis of C-reactive protein (CRP) by PLC/PRF/5 hepatoma cell line. *Ann N Y Acad Sci* 1989; 557: 532-3.
62. Ballou SP, Kushner I. C-reactive protein and the acute phase response. *Adv Int Med* 1992; 37: 313-36.

63. Languillon J, Garayon A. Précis de Leprologie. 2.ed. Paris: Masson; 1986.
64. Sehgal VN, Bhattacharya SN, Shah Y, Sharma VK, Gupta CK. Reaction in leprosy: acute phase reactant response during and after remission. Int J Dermatol 1992; 31: 632-4.
65. Foss NT, Oliveira EB, Silva CL. Correlation between TNF production, increase of plasma C-reactive protein level and suppression of T lymphocyte response to concanavalin A during erythema nodosum leprosum. Int J Lepr Other Mycobact Dis 1993; 61: 218-26.
66. Brasil. Ministério da Saúde. Secretaria de políticas de Saúde. Departamento de Atenção Básica. Área Técnica de Dermatologia Sanitária. Legislação sobre o controle da Hanseníase no Brasil. Brasília; 2000.
67. Ridley DS, Hilson GRF. A logarithmic index of bacilli in biopsies. I. Method. Int J Lepr Other Mycobact Dis 1967; 35: 184-6.
68. Brett SJ, Payne SN, Gigg J, Burgess P, Gigg R. use of synthetic glycoconjugates containing the *Mycobacterium leprae* specific and immunodominant epitope of phenolic glycolipid-I in the serology of leprosy. Clin Exp Immunol 1986; 64: 476-83.
69. Bühner-Sekuka S, Cunha MG, Ferreira WA, Klaster PR. The use of whole blood in a dipstick assay for detection of antibodies to *Mycobacterium Ieprae*: a field evaluation. FEMS Immunol Med Microbiol 1998; 21:197-201.

70. Westermann J, Thiemann F, Gerstner L, Tatzber F, Kozák I, Bertsch T, et al. Evaluation of a new simple and rapid enzyme-linked immunosorbent assay kit for neopterin determination. *Clin Chem Lab Med* 2000; 38: 345-53.
71. Zar JH. *Biostatistical analysis*. 3th ed. New Jersey: Prentice Hall; 1996.
72. Payne SN, Drapper P, Rees RJW. Sorological activity of purified glycolipid from *Mycobacterium leprae*. *Int J Lepr Other Mycobact Dis* 1982; 50: 220-21.
73. Saad MHF, Medeiros MA, Gallo MEN, Gontijo PP, Fonseca LS. IgM immunoglobulins reacting with the phenolic glycolipid antigen from *Mycobacterium leprae* in sera of leprosy patients and their contacts. *Mem Inst Oswaldo Cruz* 1990; 85: 191-4.
74. Cunha MGS. Níveis de anti-PGL-I no soro de pacientes com hanseníase tratados com quinolona e poliquimioterapia. [dissertação]. Ribeirão Preto: Faculdade de Medicina, Universidade de São Paulo; 1998.
75. Bonato VLD. Correlação dos anticorpos anti-PGL-I com o índice baciloscópico, a reação de Mitsuda, o tratamento poliquimioterápico e as interleucinas nas diferentes formas da hanseníase. [dissertação]. Ribeirão Preto: Faculdade de Medicina, Universidade de São Paulo; 1995.
76. Oskam L, Slim E, Bühner-Sékula S. Serology: recent developments, strengths, limitations and prospects: a state of the art overview. *Lepr Rev* 2003; 74: 196-205.

77. Bach MA, Wallach D, Flageul B, Hoffenbach A, Cottenot F. Antibodies to phenolic glycolipid I and to whole *Mycobacterium leprae* in leprosy patients: evolution during therapy. *Int J Lepr Other Mycobact Dis* 1986; 54: 256-67.
78. Koster FT, Scollard DM, Umland ET, Fishbein DB, Hanly WC, Brennan PJ, et al. Cellular and humoral immune response to a phenolic glycolipid antigen (PGL-I) in patients with leprosy. *J Clin Microbiol* 1987; 25: 551-6.
79. Chanteau S, Cartel JL, Roux J, Plichart R, Bach MA. Comparison of synthetic antigens for detecting antibodies to phenolic glycolipid I in patients with leprosy and their household contacts. *J Infect Dis* 1988; 157: 770-6.
80. Roche PW, Britton WJ, Failbus SS, Williams D, Pradhan HM, Theuvenet WJ. Operational value of serological measurements in multibacillary leprosy patients: clinical and bacteriological correlates of antibody responses. *Int J Lepr Other Mycobact Dis* 1990; 58: 480-90.
81. Chanteau S, Cartel JL, Celerier P, Plichart R, Desforges S, Roux J. PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy. *Int J Lepr Other Mycobact Dis* 1989; 57: 735-43.
82. Repka JCD, Brana LR, Fabricio LH, Lemos AL, Penteado SRF, Stahike P. Imunologia na hanseníase — Aspectos de avaliação imunológica no tratamento. *Arq Biol Tecnol* 1991; 34: 53-60.
83. Douglas JT, Steven LM, Fajardo T, Cellona RV, Madarang MG, Abalos RM, et al. The effects of chemotherapy on antibody levels in lepromatous patients. *Lepr Rev* 1988; 59: 127-35.

84. Cho SN, Cellona RV, Villahermosa LG, Fajardo Jr TT, Balagon MVF, Abalos RM. et al. Detection of phenolic glycolipid I of *Mycobacterium leprae* in sera from leprosy patients before and after start of multidrug therapy. Clin Diagn Lab Immunol 2001; 8: 1138-42.
85. Schmutzhard E, Fuchs D, Hausen A, Reibnegger G, Wachter. H Is neopterin a marker of cell mediated immune response helpful in classifying leprosy? East Afr Med J 1986; 63: 577-80.
86. Immanuel C, Swamy R, Kannapiran M, Vijayalakshmi S, Sundaram V, Jaganath K. Neopterin as a marker for cell mediated immunity in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 1997; 1:175-80.
87. Lambin P, Desjobert H, Debbia M, Fine JM, Muller JY. Serum neopterin and beta 2-microglobulin in anti-HIV positive blood donors. Lancet 1986; 22: 1216.
88. Immanuel C, Victor L, Cheivi KS, Padmapriyadarsini C, Rehman F, Lliayas S, et al. Serum neopterin level in HIV infected patients with & without tuberculosis. Indian J Med Res 2005; 121: 220-5.
89. Fleury RN. Patologia e manifestações viscerais. In. Noções de Hansenologia. 2.ed. Bauru: Centro de Estudos "Dr Reynaldo Quagliato". Instituto Lauro de Souza Lima; 2000. p.63-71.
90. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80.

91. Volanakis JE, Kaplan MH. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. *Proc Soc Exp Biol Med* 1971; 136: 612-4.
92. Robey FA, Jones KD, Tanaka T, Liu TV. Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein. *J Biol Chem* 1984; 259: 7311-6.
93. Robey FA, Jones KD, Steinberg AD. C-reactive protein mediates the solubilization of nuclear DNA by complement *in vitro*. *J Exp Med* 1985; 161:1344-56.
94. Mortensen RF, Osmand AP, Lint TF, Gewurz H. Interaction of C-reactive protein with lymphocytes and monocytes: complement-dependent adherence and phagocytosis. *J Immunol* 1976; 117: 774-81.
95. Pepys MB. C-reactive protein fifty years on. *Lancet* 1981; 1: 653-7.
96. Ribeiro MA. C-reactive protein: Re-evaluation of a diagnostic laboratory test. *Br J I Dis* 1997; 1: 212-25.
97. Stefani MMA, Martelli CMT, Morais-Neto OL, Martelli P, Costa MB, Andrade ALSS. Assessment of anti-PGL-I as a prognostic marker of leprosy reaction. *I J Lepr Other Mycobact Dis* 1988; 66: 356-64.
98. Cunha MGS. Episódios reacionais e relação com recidiva em doentes com hanseníase multibacilar tratados com diferentes esquemas terapêuticos. Tese [doutorado] Ribeirão Preto: Faculdade de Medicina, Universidade de São Paulo; 2001.

Referências Bibliográficas

99. Nath I, Vemuri N, Reddi AL, Jain S, Brooks P, Colston MJ, et al. The effect of antigen presenting cells on the cytokine profiles of stable and reactional lepromatous leprosy. *Immunol Lett* 2000; 75: 69-76.
100. Roche PW, Le Master J, Butlin CR. Risk factors for type 1 reactions in leprosy. *Int J Lepr* 1997; 65: 450-5.
101. Brett SJ, Lowe C, Payne SN, Draper P. Phenolic glycolipid I of *Mycobacterium leprae* causes nonspecific inflammation but has no effect on cell-mediated responses in mice. *Infect Immun* 1984; 46: 8028.
102. Fournie JJ, Adams E, Mullins RJ, Basten A. Inhibition of human lymphoproliferative responses by mycobacterial phenolic glycolipids. *Infect Immun* 1989; 57:3653-9
103. Faber WR, Iyer AM, Fajardo TT, Dekker I, Villahermosa LG, Abalos RM et al. Serial measurement of serum cytokines, cytokine receptors and neopterin in leprosy patients with reversal reactions. *Lepr Rev* 2004; 75: 274-81.
104. Foss NT. Proteína C reativa e fator de necrose tumoral na hanseníase. Tese [Livre Docência]. Ribeirão Preto: Faculdade de Medicina, Universidade de São Paulo; 1991.
105. Kaplan MH. C-reactive protein: relation to disease and pathological significance. *Ann N Y Acad Sci* 1982; 389: 419-22.
106. Volanakis JE. Complement activation by C-reactive protein complexes. *Ann N Y Acad Sci* 1982; 389: 235-49.

Referências Bibliográficas

107. Gotschlich EC. C-reactive protein: a historical overview. *Ann N Y Acad Sci* 1989; 557: 9-18.